NDC 0299-5980

Mirvaso

Brimonidine Tartrate

Mirvaso is a Topical Gel in the Human Prescription Drug category. It is labeled and distributed by Galderma Laboratories, L.p.. The primary component is Brimonidine Tartrate.

Product ID0299-5980_932a5eae-8406-4111-ac52-6ed7028d87da
NDC0299-5980
Product TypeHuman Prescription Drug
Proprietary NameMirvaso
Generic NameBrimonidine Tartrate
Dosage FormGel
Route of AdministrationTOPICAL
Marketing Start Date2013-08-23
Marketing CategoryNDA / NDA
Application NumberNDA204708
Labeler NameGalderma Laboratories, L.P.
Substance NameBRIMONIDINE TARTRATE
Active Ingredient Strength5 mg/g
Pharm ClassesAdrenergic alpha-Agonists [MoA],alpha-Adrenergic Agonist [EPC]
NDC Exclude FlagN
Listing Certified Through2022-12-31

Packaging

NDC 0299-5980-00

1 TUBE in 1 BLISTER PACK (0299-5980-00) > 2 g in 1 TUBE
Marketing Start Date2013-08-23
NDC Exclude FlagN
Sample Package?N

NDC SPL Data Element Entries

NDC 0299-5980-35 [00299598035]

Mirvaso GEL
Marketing CategoryNDA
Application NumberNDA204708
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitGM
Marketing Start Date2013-08-23

NDC 0299-5980-02 [00299598002]

Mirvaso GEL
Marketing CategoryNDA
Application NumberNDA204708
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2013-08-23

NDC 0299-5980-30 [00299598030]

Mirvaso GEL
Marketing CategoryNDA
Application NumberNDA204708
Product TypeHUMAN PRESCRIPTION DRUG
Billing UnitGM
Marketing Start Date2013-08-23

NDC 0299-5980-00 [00299598000]

Mirvaso GEL
Marketing CategoryNDA
Application NumberNDA204708
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2013-08-23

NDC 0299-5980-45 [00299598045]

Mirvaso GEL
Marketing CategoryNDA
Application NumberNDA204708
Product TypeHUMAN PRESCRIPTION DRUG
Marketing Start Date2013-08-23

Drug Details

Active Ingredients

IngredientStrength
BRIMONIDINE TARTRATE5 mg/g

OpenFDA Data

SPL SET ID:f6a4353f-ae69-4214-901f-e5d42a6fbde7
Manufacturer
UNII
RxNorm Concept Unique ID - RxCUI
  • 1437707
  • 1437709
  • UPC Code
  • 0302995980306
  • Pharmacological Class

    • Adrenergic alpha-Agonists [MoA]
    • alpha-Adrenergic Agonist [EPC]
    • Adrenergic alpha-Agonists [MoA]
    • alpha-Adrenergic Agonist [EPC]

    NDC Crossover Matching brand name "Mirvaso" or generic name "Brimonidine Tartrate"

    NDCBrand NameGeneric Name
    0299-5980Mirvasobrimonidine tartrate
    0023-9177ALPHAGAN Pbrimonidine tartrate
    0023-9321ALPHAGAN Pbrimonidine tartrate
    17478-715BrimonidineBrimonidine Tartrate
    50090-1046BrimonidineBrimonidine Tartrate
    14445-400Brimonidine TartrateBrimonidine Tartrate
    24208-411Brimonidine TartrateBrimonidine Tartrate
    25685-715Brimonidine Tartratebrimonidine tartrate
    42843-501Brimonidine TartrateBrimonidine Tartrate
    50090-1800Brimonidine TartrateBrimonidine Tartrate
    50090-4224Brimonidine TartrateBrimonidine Tartrate
    60505-0564Brimonidine Tartratebrimonidine tartrate
    61314-143Brimonidine TartrateBrimonidine Tartrate
    61314-144Brimonidine TartrateBrimonidine Tartrate
    63629-8792Brimonidine TartrateBrimonidine Tartrate
    24208-537LUMIFY Redness Reliever Eye DropsBRIMONIDINE TARTRATE

    Trademark Results [Mirvaso]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    MIRVASO
    MIRVASO
    85455333 4437024 Live/Registered
    NESTLÉ SKIN HEALTH S.A.
    2011-10-25

    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.